Safety, Efficacy and Individualized Dose-Finding Study for Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
This study is for a new non-cytoreductive treatment approach for polycythemia vera, based on the mechanism of iron balance maintenance in the body by the natural hormone hepcidin.
The treatment candidate, PTG-300*, is designed to help regulate the amount of iron available for the production of red blood cells. This ongoing study, conducted at sites across the U.S., is evaluating the ability for PTG-300 administration to control the relative number of red blood cells (hematocrit level), reduce, delay or eliminate phlebotomy, and improve measures of quality of life.
*PTG-300 is an investigational therapy not approved by the U.S. Food and Drug Administration. The safety and efficacy of PTG-300 has not been determined.